Budget cuts will impede research into rare and common diseases

03/11/2013 | BioCentury · In-PharmaTechnologist.com

Spending cuts at the FDA and NIH threaten research that translates basic science discoveries into clinically relevant treatments, says FasterCures Executive Director Margaret Anderson. Very little is known about most rare diseases, and basic research such as that being done at NIH's National Center for Advancing Translational Sciences is critically important, says Diane Dorman, president of the Alliance for a Stronger FDA.

View Full Article in:

BioCentury · In-PharmaTechnologist.com

Published in Brief: